• Explore /
  • Poster
  • / DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.

DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.

Abstract Video & Slides Poster

Authors

Samuel Klempner

Samuel J Klempner

The Angeles Clinic and Research Institute, Los Angeles, CA

Samuel J Klempner , Joseph Chao , Hope Elizabeth Uronis , Cynthia A. Sirard , Michael Kagey , Jason Baum , James Song , Jin Wang , In-Ho Kim , Keun Wook Lee , Do-Youn Oh , Bassam Bassam Sonbol , Zev A. Wainberg , Jaffer A. Ajani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04363801

DOI

10.1200/JCO.2022.40.4_suppl.292

Abstract #

292

Poster Bd #

F4

Abstract Disclosures

Similar Posters

First Author: Samuel J Klempner

First Author: Keun-Wook Lee

First Author: Kohei Shitara

First Author: Patricio Eduardo Yanez